CB Insights
Technology Market Intelligence
Technology Market Intelligence
OliPass Corporation (KOSDAQ: 244460) is a biopharmaceutical company that focuses on developing antisense medicines based on peptide nucleic acid (PNA) technology.
Company (IPO / Went public)
Phone: +82-31-8060-8200
Ace Dongbaek Tower
20th Floor
Gyeonggi, 17015
South Korea
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | Dec 19, 2013 | Nov 25, 2014 | Patent |
| Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | Dec 17, 2013 | Nov 11, 2014 | Patent |
| Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | Dec 18, 2013 | Oct 14, 2014 | Patent |
| Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | Mar 13, 2009 | Mar 25, 2014 | Patent |
| Scn9a antisense pain killer | Jan 23, 2018 | Application |
